1. Unites States Food and Drug Administration . ANDEXXA (coagulation factor Xa (recombinant), inactivated-zhzo). 2019; Accessed February 24, 2021. www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/andexxa-coagulation-factor-xa-recombinant-inactivated-zhzo
Google Scholar2. Andexxa® . Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Accessed February 24, 2021. http://online.lexi.com
Google Scholar3. Connolly, SJ, Crowther, M, Eikelboom, JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380(14):1326–1335.
Google Scholar | Crossref | Medline4. Levy, JH, Ageno, W, Chan, NC, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2015;14(3):623–627.
Google Scholar | Crossref5. Nederpelt, CJ, Naar, L, Sylvester, KW, et al. Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa. J Thromb Haemost. 2020;18(10):2532–2541.
Google Scholar | Crossref | Medline6. Ageno, W, Gallus, AS, Wittkowsky, A, Crowther, M, Hylek, EM, Palareti, G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 suppl):e44S–e88S.
Google Scholar | Crossref | Medline | ISI7. Baglin, T, Hillarp, A, Tripodi, A. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11:756–760.
Google Scholar | Crossref8. Gosselin, R, Adcock, D, Bates, S, et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2018;118(3):437–450.
Google Scholar | Crossref | Medline9. Barrett, YC, Wang, Z, Knabb, RM. A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb Hemost. 2013;19(5):522–528.
Google Scholar | SAGE Journals10. Samuelson, BT, Cuker, A, Siegal, DM. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest 2017;151(1):127–138.
Google Scholar | Crossref | Medline11. Gosselin, R, Francart, S, Hawes, E. Heparin-calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level? Ann Pharmacother. 2015;49(7):777–783.
Google Scholar | SAGE Journals | ISI12. Billoir, P, Barbay, V, Joly, L. Anti-Xa oral anticoagulant plasma concentration assay in real life: rivaroxaban and apixaban quantification in emergency with LMWH calibrator. Ann Pharmacother. 2019;53(4):341–347.
Google Scholar | SAGE Journals | ISI13. Sarode, R, Milling, TJ, Refaai, MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagnoists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234–1243.
Google Scholar | Crossref | Medline | ISI